Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 8/2021

Open Access 01-08-2021 | Familial Adenomatous Polyposis | Special Article

Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2020 for the Clinical Practice of Hereditary Colorectal Cancer

Authors: Naohiro Tomita, Hideyuki Ishida, Kohji Tanakaya, Tatsuro Yamaguchi, Kensuke Kumamoto, Toshiaki Tanaka, Takao Hinoi, Yasuyuki Miyakura, Hirotoshi Hasegawa, Tetsuji Takayama, Hideki Ishikawa, Takeshi Nakajima, Akiko Chino, Hideki Shimodaira, Akira Hirasawa, Yoshiko Nakayama, Shigeki Sekine, Kazuo Tamura, Kiwamu Akagi, Yuko Kawasaki, Hirotoshi Kobayashi, Masami Arai, Michio Itabashi, Yojiro Hashiguchi, Kenichi Sugihara, Japanese Society for Cancer of the Colon, Rectum

Published in: International Journal of Clinical Oncology | Issue 8/2021

Login to get access

Abstract

Hereditary colorectal cancer (HCRC) accounts for < 5% of all colorectal cancer cases. Some of the unique characteristics commonly encountered in HCRC cases include early age of onset, synchronous/metachronous cancer occurrence, and multiple cancers in other organs. These characteristics necessitate different management approaches, including diagnosis, treatment or surveillance, from sporadic colorectal cancer management. There are two representative HCRC, named familial adenomatous polyposis and Lynch syndrome. Other than these two HCRC syndromes, related disorders have also been reported. Several guidelines for hereditary disorders have already been published worldwide. In Japan, the first guideline for HCRC was prepared by the Japanese Society for Cancer of the Colon and Rectum (JSCCR), published in 2012 and revised in 2016. This revised version of the guideline was immediately translated into English and published in 2017. Since then, several new findings and novel disease concepts related to HCRC have been discovered. The currently diagnosed HCRC rate in daily clinical practice is relatively low; however, this is predicted to increase in the era of cancer genomic medicine, with the advancement of cancer multi-gene panel testing or whole genome testing, among others. Under these circumstances, the JSCCR guidelines 2020 for HCRC were prepared by consensus among members of the JSCCR HCRC Guideline Committee, based on a careful review of the evidence retrieved from literature searches, and considering the medical health insurance system and actual clinical practice settings in Japan. Herein, we present the English version of the JSCCR guidelines 2020 for HCRC.
Appendix
Available only for authorised users
Literature
1.
Japanese Society for the Cancer of the Colon and Rectum (2019) JSCCR guidelines 2019 for the treatment of colorectal cancer. Kanehara & Co. Ltd, Tokyo
2.
Jaeschke R, Guyatt GH, Dellinger P et al (2008) GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. BMJ 337:a744PubMedCrossRef
3.
Lichtenstein P, Holm NV, Verkasalo PK et al (2000) Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343:78–85PubMedCrossRef
4.
De Rosa M, Pace U, Rega D et al (2015) Genetics, diagnosis and management of colorectal cancer (review). Oncol Rep 34:1087–1096PubMedCrossRef
5.
Macaron C, Leach BH, Burke CA (2015) Hereditary colorectal cancer syndromes and genetic testing. J Surg Oncol 111:103–111PubMedCrossRef
6.
Hampel H, Frankel WL, Martin E et al (2005) Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 352:1851–1860PubMedCrossRef
7.
8.
Canard G, Lefevre JH, Colas C et al (2012) Screening for Lynch syndrome in colorectal cancer: are we doing enough? Ann Surg Oncol 19:809–816PubMedCrossRef
9.
Julie C, Tresallet C, Brouquet A et al (2008) Identification in daily practice of patients with Lynch syndrome (hereditary nonpolyposis colorectal cancer): revised Bethesda guidelines-based approach versus molecular screening. Am J Gastroenterol 103:2825–2835PubMedCrossRef
10.
Chika N, Eguchi H, Kumamoto K et al (2017) Prevalence of Lynch syndrome and Lynch-like syndrome among patients with colorectal cancer in a Japanese hospital-based population. Jpn J Clin Oncol 47:108–117PubMedCrossRef
11.
Kiyozumi Y, Matsubayashi H, Horiuchi Y et al (2019) Germline mismatch repair gene variants analyzed by universal sequencing in Japanese cancer patients. Cancer Med 8:5534–5543PubMedPubMedCentralCrossRef
12.
Vasen HF, Möslein G, Alonso A et al (2008) Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut 57:704–713PubMedCrossRef
13.
National Comprehensive Cancer Network (2019) NCCN clinical practice guidelines in oncology: genetic/familial high–risk assessment: colorectal. Version 2. 2019. Available via http://​www.​nccn.​org
14.
Stoffel E, Mukherjee B, Raymond VM et al (2009) Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology 137:1621–1627PubMedCrossRef
15.
Ishida H (2018) Clinical practice for patients with hereditary colorectal cancer. J Jpn Surg Soc 119:62–66
16.
17.
Takayama T, Ohi M, Hayashi T et al (2001) Analysis of K-ras, APC, and beta-catenin in aberrant crypt foci in sporadic adenoma, cancer, and familial adenomatous polyposis. Gastroenterology 121:599–611PubMedCrossRef
18.
Vogelstein B, Fearon ER, Hamilton SR et al (1988) Genetic alterations during colorectal tumor development. N Engl J Med 319:525–532PubMedCrossRef
19.
Fujiyoshi K, Yamaguchi T, Kakuta M et al (2017) Predictive model for high-frequency microsatellite instability in colorectal cancer patients over 50 years of age. Cancer Med 6:1255–1263PubMedPubMedCentralCrossRef
20.
Grover S, Kastrinos F, Steyerberg EW et al (2012) Prevalence and phenotypes of APC and MUTYH mutations in patients with multiple colorectal adenomas. JAMA 308:485–492PubMedPubMedCentralCrossRef
21.
Bussey HJR (1975) Genetic and epidemiological features of familial polyposis coli. familial polyposis coli. Johns Hopkins University Press, Baltimore and London, pp 9–17
22.
Iwama T, Tamura K, Morita T et al (2004) A clinical overview of familial adenomatous polyposis derived from the database of the Polyposis Registry of Japan. Int J Clin Oncol 9:308–316PubMedCrossRef
23.
Murata M, Utsunomiya J, Iwama T et al (1981) Frequency of adenomatosis coli in Japan. J Human Genet 26:19–30
24.
Hamilton SR, Liu B, Parsons RE et al (1995) The molecular basis of Turcot’s syndrome. N Engl J Med 332:839–847PubMedCrossRef
25.
26.
Worthley DL, Phillips KD, Wayte N et al (2012) Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS): a new autosomal dominant syndrome. Gut 61:774–779PubMedCrossRef
27.
Nagase H, Miyoshi Y, Horii A et al (1992) Correlation between the location of germ-line mutations in the APC gene and the number of colorectal polyps in familial adenomatous polyposis patients. Cancer Res 52:4055–4057PubMed
28.
Nugent KP, Phillips RK, Hodgson SV et al (1994) Phenotypic expression in familial adenomatous polyposis: partial prediction by mutation analysis. Gut 35:1622–1623PubMedPubMedCentralCrossRef
29.
Knudsen AL, Bisgaard ML, Bülow S (2003) Attenuated familial adenomatous polyposis (AFAP). A review of the literature. Fam Cancer 2:43–55PubMedCrossRef
30.
Aretz S, Stienen D, Friedrichs N et al (2007) Somatic APC mosaicism: a frequent cause of familial adenomatous polyposis (FAP). Hum Mutat 28:985–992PubMedCrossRef
31.
Hes FJ, Nielsen M, Bik EC et al (2008) Somatic APC mosaicism: an underestimated cause of polyposis coli. Gut 57:71–76PubMedCrossRef
32.
Kim B, Won D, Jang M et al (2019) Next-generation sequencing with comprehensive bioinformatics analysis facilitates somatic mosaic APC gene mutation detection in patients with familial adenomatous polyposis. BMC Med Genomics 12:103PubMedPubMedCentralCrossRef
33.
Jansen AM, Crobach S, Geurts-Giele WR et al (2017) Distinct patterns of somatic mosaicism in the APC gene in neoplasms from patients with unexplained adenomatous polyposis. Gastroenterology 152(546–549):e3
34.
Al-Tassan N, Chmiel NH, Maynard J et al (2002) Inherited variants of MYH associated with somatic G: C→T: a mutations in colorectal tumors. Nat Genet 30:227–232PubMedCrossRef
35.
Nielsen M, Franken PF, Reinards TH et al (2005) Multiplicity in polyp count and extracolonic manifestations in 40 Dutch patients with MYH associated polyposis coli (MAP). J Med Genet 42:e54PubMedPubMedCentralCrossRef
36.
Lubbe SJ, Di Bernardo MC, Chandler IP et al (2009) Clinical implications of the colorectal cancer risk associated with MUTYH mutation. J Clin Oncol 27:3975–3980PubMedCrossRef
37.
Palles C, Cazier JB, Howarth KM et al (2013) Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet 45:136–144PubMedCrossRef
38.
Spier I, Holzapfel S, Altmüller J et al (2015) Frequency and phenotypic spectrum of germline mutations in POLE and seven other polymerase genes in 266 patients with colorectal adenomas and carcinomas. Int J Cancer 137:320–331PubMedCrossRef
39.
Bellido F, Pineda M, Aiza G et al (2016) POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med 18:325–332PubMedCrossRef
40.
Bianchi LK, Burke CA, Bennett AE et al (2008) Fundic gland polyp dysplasia is common in familial adenomatous polyposis. Clin Gastroenterol Hepatol 6:180–185PubMedCrossRef
41.
Iida M, Yao T, Itoh H et al (1989) Natural history of duodenal lesions in Japanese patients with familial adenomatosis coli (Gardner’s syndrome). Gastroenterology 96:1301–1306PubMedCrossRef
42.
Moozar KL, Madlensky L, Berk T et al (2002) Slow progression of periampullary neoplasia in familial adenomatous polyposis. J Gastrointest Surg 6:831–837PubMedCrossRef
43.
44.
Iida M, Hizawa K, Matsumoto T et al (1997) Long-term course of gastric and duodenal lesions in familial adenomatous polyposis. Stomach Intest 32:563–576
45.
Galle TS, Juel K, Bülow S (1999) Causes of death in familial adenomatous polyposis. Scand J Gastroenterol 34:808–812PubMedCrossRef
46.
Offerhaus GJ, Giardiello FM, Krush AJ et al (1992) The risk of upper gastrointestinal cancer in familial adenomatous polyposis. Gastroenterology 102:1980–1982PubMedCrossRef
47.
Park JG, Park KJ, Ahn YO et al (1992) Risk of gastric cancer among Korean familial adenomatous polyposis patients. Report of three cases. Dis Colon Rectum 35:996–998PubMedCrossRef
48.
49.
Yamaguchi T, Ishida H, Ueno H et al (2016) Upper gastrointestinal tumours in Japanese familial adenomatous polyposis patients. Jpn J Clin Oncol 46:310–315PubMedPubMedCentralCrossRef
50.
Spigelman AD, Williams CB, Talbot IC et al (1989) Upper gastrointestinal cancer in patients with familial adenomatous polyposis. Lancet 2:783–785PubMedCrossRef
51.
Lopez-Ceron M, van den Broek FJ, Mathus-Vliegen EM et al (2013) The role of high-resolution endoscopy and narrow-band imaging in the evaluation of upper GI neoplasia in familial adenomatous polyposis. Gastrointest Endosc 77:542–550PubMedCrossRef
52.
Groves CJ, Saunders BP, Spigelman AD et al (2002) Duodenal cancer in patients with familial adenomatous polyposis (FAP): results of a 10 year prospective study. Gut 50:636–641PubMedPubMedCentralCrossRef
53.
54.
Saurin JC, Gutknecht C, Napoleon B et al (2004) Surveillance of duodenal adenomas in familial adenomatous polyposis reveals high cumulative risk of advanced disease. J Clin Oncol 22:493–498PubMedCrossRef
55.
Bertario L, Presciuttini S, Sala P et al (1994) Causes of death and postsurgical survival in familial adenomatous polyposis: results from the Italian Registry. Italian Registry of Familial Polyposis Writing Committee. Semin Surg Oncol 10:225–234PubMedCrossRef
56.
Parc Y, Piquard A, Dozois RR et al (2004) Long-term outcome of familial adenomatous polyposis patients after restorative coloproctectomy. Ann Surg 239:378–382PubMedPubMedCentralCrossRef
57.
Speake D, Evans DG, Lalloo F et al (2007) Desmoid tumours in patients with familial adenomatous polyposis and desmoid region adenomatous polyposis coli mutations. Br J Surg 94:1009–1013PubMedCrossRef
58.
Saito Y, Hinoi T, Ueno H et al (2016) Risk Factors for the Development of desmoid tumor after colectomy in patients with familial adenomatous polyposis: multicenter retrospective cohort study in Japan. Ann Surg Oncol 23:559–565PubMedCrossRef
59.
Sturt NJ, Gallagher MC, Bassett P et al (2004) Evidence for genetic predisposition to desmoid tumours in familial adenomatous polyposis independent of the germline APC mutation. Gut 53:1832–1836PubMedPubMedCentralCrossRef
60.
Iwama T, Mishima Y, Utsunomiya J (1993) The impact of familial adenomatous polyposis on the tumorigenesis and mortality at the several organs. Its rational treatment. Ann Surg 217:101–108PubMedPubMedCentralCrossRef
61.
Knudsen AL, Bulow S (2001) Desmoid tumour in familial adenomatous polyposis. A review of literature. Fam Cancer 1:111–119PubMedCrossRef
62.
Nieuwenhuis MH, De Vos Tot Nederveen Cappel W, Botma A et al (2008) Desmoid tumors in a dutch cohort of patients with familial adenomatous polyposis. Clin Gastroenterol Hepatol 6:215–219PubMedCrossRef
63.
Latchford AR, Sturt NJ, Neale K et al (2006) A 10-year review of surgery for desmoid disease associated with familial adenomatous polyposis. Br J Surg 93:1258–1264PubMedCrossRef
64.
65.
Benoit L, Faivre L, Cheynel N et al (2007) 3’Mutation of the APC gene and family history of FAP in a patient with apparently sporadic desmoid tumors. J Clin Gastroenterol 41:297–300PubMedCrossRef
66.
Yamano T, Hamanaka M, Babaya A et al (2017) Management strategies in Lynch syndrome and familial adenomatous polyposis: a national healthcare survey in Japan. Cancer Sci 108:243–249PubMedPubMedCentralCrossRef
67.
Walter T, Zhenzhen Wang C, Guillaud O et al (2017) Management of desmoid tumours: a large national database of familial adenomatous patients shows a link to colectomy modalities and low efficacy of medical treatments. United Eur Gastroenterol J 5:735–741CrossRef
68.
Church J, Lynch C, Neary P et al (2008) A desmoid tumor-staging system separates patients with intra-abdominal, familial adenomatous polyposis-associated desmoid disease by behavior and prognosis. Dis Colon Rectum 51:897–901PubMedCrossRef
69.
Bertario L, Russo A, Sala P et al (2001) Genotype and phenotype factors as determinants of desmoid tumors in patients with familial adenomatous polyposis. Int J Cancer 95:102–107PubMedCrossRef
70.
Nieuwenhuis MH, Lefevre JH, Bulow S et al (2011) Family history, surgery, and APC mutation are risk factors for desmoid tumors in familial adenomatous polyposis: an international cohort study. Dis Colon Rectum 54:1229–1234PubMedCrossRef
71.
Church J, Xhaja X, LaGuardia L et al (2015) Desmoids and genotype in familial adenomatous polyposis. Dis Colon Rectum 58:444–448PubMedCrossRef
72.
Tsukada K, Church JM, Jagelman DG et al (1991) Systemic cytotoxic chemotherapy and radiation therapy for desmoid in familial adenomatous polyposis. Dis Colon Rectum 34:1090–1092PubMedCrossRef
73.
Hansmann A, Adolph C, Vogel T et al (2004) High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer 100:612–620PubMedCrossRef
74.
75.
Quast DR, Schneider R, Burdzik E et al (2016) Long-term outcome of sporadic and FAP-associated desmoid tumors treated with high-dose selective estrogen receptor modulators and sulindac: a single-center long–term observational study in 134 patients. Fam Cancer 15:31–40PubMedCrossRef
76.
Nieuwenhuis MH, Mathus-Vliegen EM, Baeten CG et al (2011) Evaluation of management of desmoid tumours associated with familial adenomatous polyposis in Dutch patients. Br J Cancer 104:37–42PubMedCrossRef
77.
Desurmont T, Lefèvre JH, Shields C et al (2015) Desmoid tumour in familial adenomatous polyposis patients: responses to treatments. Fam Cancer 14:31–39PubMedCrossRef
78.
Clark SK, Neale KF, Landgrebe JC et al (1999) Desmoid tumours complicating familial adenomatous polyposis. Br J Surg 86:1185–1189PubMedCrossRef
79.
Chugh R, Wathen JK, Patel SR et al (2010) Efficacy of imatinib in aggressive fibromatosis: results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. Clin Cancer Res 16:4884–4891PubMedCrossRef
80.
Kono T, Tomita I, Chisato N et al (2004) Successful low-dose chemotherapy using vinblastine and methotrexate for the treatment of an ileoanal pouch mesenteric desmoid tumor: report of a case. Dis Colon Rectum 47:246–249PubMedCrossRef
81.
Gega M, Yanagi H, Yoshikawa R et al (2006) Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis. J Clin Oncol 24:102–105PubMedCrossRef
82.
Amano K, Chika N, Ito T et al (2017) The characteristics and treatment outcomes for desmoid tumors associated with familial adenomatous polyposis. Gan To Kagaku Ryoho 44:1449–1451PubMed
83.
Inoue Y, Ishida H, Ueno H et al (2017) The treatment of desmoid tumors associated with familial adenomatous polyposis: the results of a Japanese multicenter observational study. Surg Today 47:1259–1267PubMedCrossRef
84.
Howard JH, Pollock RE (2016) Intra-abdominal and abdominal wall desmoid fibromatosis. Oncol Ther 4:57–72PubMedCrossRef
85.
Iwama T, Kuwabara K, Ushiama M et al (2009) Identification of somatic APC mutations in recurrent desmoid tumors in a patient with familial adenomatous polyposis to determine actual recurrence of the original tumor or de novo occurrence. Fam Cancer 8:51–54PubMedCrossRef
86.
Smith AJ, Lewis JJ, Merchant NB et al (2000) Surgical management of intra-abdominal desmoid tumours. Br J Surg 87:608–613PubMedCrossRef
87.
Church J, Berk T, Boman BM et al (2005) Staging intra-abdominal desmoid tumors in familial adenomatous polyposis: a search for a uniform approach to a troubling disease. Dis Colon Rectum 48:1528–1534PubMedCrossRef
88.
Distante S, Nasioulas S, Somers GR et al (1996) Familial adenomatous polyposis in a 5 year old child: a clinical, pathological, and molecular genetic study. J Med Genet 33:157–160PubMedPubMedCentralCrossRef
89.
Nielsen M, Hes FJ, Nagengast FM et al (2007) Germline mutations in APC and MUTYH are responsible for the majority of families with attenuated familial adenomatous polyposis. Clin Genet 71:427–433PubMedCrossRef
90.
Burt RW, Leppert MF, Slattery ML et al (2004) Genetic testing and phenotype in a large kindred with attenuated familial adenomatous polyposis. Gastroenterology 127:444–451PubMedCrossRef
91.
Vasen HF, van Duijvendijk P, Buskens E et al (2001) Decision analysis in the surgical treatment of patients with familial adenomatous polyposis: a Dutch–Scandinavian collaborative study including 659 patients. Gut 49:231–235PubMedPubMedCentralCrossRef
92.
Kartheuser A, Stangherlin P, Brandt D et al (2006) Restorative proctocolectomy and ileal pouch-anal anastomosis for familial adenomatous polyposis revisited. Fam Cancer 5:241–260PubMedCrossRef
93.
Ueno H, Kobayashi H, Konishi T et al (2016) Prevalence of laparoscopic surgical treatment and its clinical outcomes in patients with familial adenomatous polyposis in Japan. Int J Clin Oncol 21:713–722PubMedCrossRef
94.
Konishi T, Ishida H, Ueno H et al (2016) Feasibility of laparoscopic total proctocolectomy with ileal pouch-anal anastomosis and total colectomy with ileorectal anastomosis for familial adenomatous polyposis: results of a nationwide multicenter study. Int J Clin Oncol 21:953–961PubMedCrossRef
95.
Johansen C, Bitsch M, Bülow S (1990) Fertility and pregnancy in women with familial adenomatous polyposis. Int J Colorectal Dis 5:203–206PubMedCrossRef
96.
Olsen KØ, Juul S, Bülow S et al (2003) Female fecundity before and after operation for familial adenomatous polyposis. Br J Surg 90:227–231PubMedCrossRef
97.
Nieuwenhuis MH, Douma KF, Bleiker EM et al (2010) Female fertility after colorectal surgery for familial adenomatous polyposis: a nationwide cross-sectional study. Ann Surg 252:341–344PubMedCrossRef
98.
Oresland T, Palmblad S, Ellstrom M et al (1994) Gynaecological and sexual function related to anatomical changes in the female pelvis after restorative proctocolectomy. Int J Colorectal Dis 9:77–81PubMedCrossRef
99.
Bartels SA, D’Hoore A, Cuesta MA et al (2012) Significantly increased pregnancy rates after laparoscopic restorative proctocolectomy: a cross-sectional study. Ann Surg 256:1045–1048PubMedCrossRef
100.
Remzi FH, Gorgun E, Bast J et al (2005) Vaginal delivery after ileal pouch-anal anastomosis: a word of caution. Dis Colon Rectum 48:1691–1699PubMedCrossRef
101.
Juhasz ES, Fozard B, Dozois RR et al (1995) Ileal pouch-anal anastomosis function following childbirth. An extended evaluation. Dis Colon Rectum 38:159–165PubMedCrossRef
102.
Iwama T (1978) A pathomorphological study of adenomatous polyposis. J Jpn Surg Soc 79:10–24
103.
Rozen P, Macrae F (2006) Familial adenomatous polyposis: the practical applications of clinical and molecular screening. Fam Cancer 5:227–235PubMedCrossRef
104.
Crabtree MD, Tomlinson IP, Talbot IC et al (2001) Variability in the severity of colonic disease in familial adenomatous polyposis results from differences in tumour initiation rather than progression and depends relatively little on patient age. Gut 49:540–543PubMedPubMedCentralCrossRef
105.
Kartheuser AH, Parc R, Penna CP et al (1996) Ileal pouch-anal anastomosis as the first choice operation in patients with familial adenomatous polyposis: a ten-year experience. Surgery 119:615–623PubMedCrossRef
106.
Rozen P, Samuel Z, Rabau M et al (2001) Familial adenomatous polyposis at the Tel Aviv Medical Center: demographic and clinical features. Fam Cancer 1:75–82PubMedCrossRef
107.
108.
Lynch PM, Morris JS, Wen S et al (2016) A proposed staging system and stage-specific interventions for familial adenomatous polyposis. Gastrointest Endosc 84(115–125):e114
109.
Septer S, Lawson CE, Anant S et al (2016) Familial adenomatous polyposis in pediatrics: natural history, emerging surveillance and management protocols, chemopreventive strategies, and areas of ongoing debate. Fam Cancer 15:477–485PubMedCrossRef
110.
Thompson-Fawcett MW, Marcus VA, Redston M et al (2001) Adenomatous polyps develop commonly in the ileal pouch of patients with familial adenomatous polyposis. Dis Colon Rectum 44:347–353PubMedCrossRef
111.
Groves CJ, Beveridge LG, Swain DJ et al (2005) Prevalence and morphology of pouch and ileal adenomas in familial adenomatous polyposis. Dis Colon Rectum 48:816–823PubMedCrossRef
112.
Tajika M, Niwa Y, Bhatia V et al (2013) Risk of ileal pouch neoplasms in patients with familial adenomatous polyposis. World J Gastroenterol 19:6774–6783PubMedPubMedCentralCrossRef
113.
Hoehner JC, Metcalf AM (1994) Development of invasive adenocarcinoma following colectomy with ileoanal anastomosis for familial polyposis coli. Report of a case. Dis Colon Rectum 37:824–828PubMedCrossRef
114.
Ault GT, Nunoo-Mensah JW, Johnson L et al (2009) Adenocarcinoma arising in the middle of ileoanal pouches: report of five cases. Dis Colon Rectum 52:538–541PubMedCrossRef
115.
Angriman I, Scarpa M, Castagliuolo I (2014) Relationship between pouch microbiota and pouchitis following restorative proctocolectomy for ulcerative colitis. World J Gastroenterol 20:9665–9674PubMedPubMedCentralCrossRef
116.
Koskenvuo L, Renkonen-Sinisalo L, Järvinen HJ et al (2014) Risk of cancer and secondary proctectomy after colectomy and ileorectal anastomosis in familial adenomatous polyposis. Int J Colorectal Dis 29:225–230PubMedCrossRef
117.
Campos FG, Perez RO, Imperiale AR et al (2009) Surgical treatment of familial adenomatous polyposis: ileorectal anastomosis or restorative proctolectomy? Arq Gastroenterol 46:294–299PubMedCrossRef
118.
Nieuwenhuis MH, Bülow S, Björk J et al (2009) Genotype predicting phenotype in familial adenomatous polyposis: a practical application to the choice of surgery. Dis Colon Rectum 52:1259–1263PubMedCrossRef
119.
120.
Bülow S, Bülow C, Vasen H et al (2008) Colectomy and ileorectal anastomosis is still an option for selected patients with familial adenomatous polyposis. Dis Colon Rectum 51:1318–1323PubMedCrossRef
121.
Church J, Simmang C (2003) Practice parameters for the treatment of patients with dominantly inherited colorectal cancer (familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer). Dis Colon Rectum 46:1001–1012PubMedCrossRef
122.
Bennett RL, Steinhaus KA, Uhrich SB et al (1995) Recommendations for standardized human pedigree nomenclature. Pedigree Standardization Task Force of the National Society of Genetic Counselors. Am J Hum Genet 56:745–752PubMedPubMedCentral
123.
Bennett RL, French KS, Resta RG et al (2008) Standardized human pedigree nomenclature: update and assessment of the recommendations of the National Society of Genetic Counselors. J Genet Couns 17:424–433PubMedCrossRef
124.
Hyer W, Cohen S, Attard T et al (2019) Management of familial adenomatous polyposis in children and adolescents: position paper from the ESPGHAN Polyposis Working Group. J Pediatr Gastroenterol Nutr 68:428–441PubMedCrossRef
125.
Achatz MI, Porter CC, Brugières L et al (2017) Cancer screening recommendations and clinical management of inherited gastrointestinal cancer syndromes in childhood. Clin Cancer Res 23:e107–e114PubMedCrossRef
126.
Syngal S, Brand RE, Church JM et al (2015) ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol 110:223–262PubMedPubMedCentralCrossRef
127.
Bisgaard ML, Fenger K, Bülow S et al (1994) Familial adenomatous polyposis (FAP): frequency, penetrance, and mutation rate. Hum Mutat 3:121–125PubMedCrossRef
128.
Sinha A, Tekkis PP, Gibbons DC et al (2011) Risk factors predicting desmoid occurrence in patients with familial adenomatous polyposis: a meta-analysis. Colorectal Dis 13:1222–1229PubMedCrossRef
129.
Briggs S, Tomlinson I (2013) Germline and somatic polymerase ε and δ mutations define a new class of hypermutated colorectal and endometrial cancers. J Pathol 230:148–153PubMedPubMedCentralCrossRef
130.
Nakamura K, Nonaka S, Nakajima T et al (2017) Clinical outcomes of gastric polyps and neoplasms in patients with familial adenomatous polyposis. Endosc Int Open 5:e137–e145PubMedPubMedCentralCrossRef
131.
Nakamura S, Matsumoto T, Kobori Y et al (2002) Impact of Helicobacter pylori infection and mucosal atrophy on gastric lesions in patients with familial adenomatous polyposis. Gut 51:485–489PubMedPubMedCentralCrossRef
132.
Sakai N, Tatsuta M, Hirasawa R et al (1998) Low prevalence of Helicobacter pylori infection in patients with hamartomatous fundic polyps. Dig Dis Sci 43:766–772PubMedCrossRef
133.
Nakano K, Kawachi H, Chino A et al (2019) Phenotypic variations of gastric neoplasms in familial adenomatous polyposis are associated with endoscopic status of atrophic gastritis. Dig Endosc 32:547–556PubMedCrossRef
134.
Yaguchi K, Makazu M, Hirasawa K et al (2017) Familial adenomatous polyposis with multiple Helicobacter-negative early gastric cancers treated by endoscopic submucosal dissection. Intern Med 56:3283–3286PubMedPubMedCentralCrossRef
135.
Rudloff U (2018) Gastric adenocarcinoma and proximal polyposis of the stomach: diagnosis and clinical perspectives. Clin Exp Gastroenterol 11:447–459PubMedPubMedCentralCrossRef
136.
Maehata Y, Esaki M, Kawano S et al (2016) Management of duodenal lesions in patients with familial adenomatous polyposis. Stomach Intest 51:1593–1601
137.
Matsumoto T, Iida M, Nakamura S et al (2000) Natural history of ampullary adenoma in familial adenomatous polyposis: reconfirmation of benign nature during extended surveillance. Am J Gastroenterol 95:1557–1562PubMedCrossRef
138.
Penninga L, Svendsen LB (2011) Pancreas-preserving total duodenectomy: a 10-year experience. J Hepatobiliary Pancreat Sci 18:717–723PubMedCrossRef
139.
van Heumen BW, Nieuwenhuis MH, van Goor H et al (2012) Surgical management for advanced duodenal adenomatosis and duodenal cancer in Dutch patients with familial adenomatous polyposis: a nationwide retrospective cohort study. Surgery 151:681–690PubMedCrossRef
140.
Watanabe Y, Ishida H, Baba H et al (2017) Pancreas-sparing total duodenectomy for Spigelman stage IV duodenal polyposis associated with familial adenomatous polyposis: experience of 10 cases at a single institution. Fam Cancer 16:91–98PubMedCrossRef
141.
Walsh RM, Augustin T, Aleassa EM et al (2019) Comparison of pancreas-sparing duodenectomy (PSD) and pancreatoduodenectomy (PD) for the management of duodenal polyposis syndromes. Surgery 166:496–502PubMedCrossRef
142.
Augustin T, Moslim MA, Tang A et al (2018) Tailored surgical treatment of duodenal polyposis in familial adenomatous polyposis syndrome. Surgery 163:594–599PubMedCrossRef
143.
De Marchis ML, Tonelli F, Quaresmini D et al (2017) Desmoid tumors in familial adenomatous polyposis. Anticancer Res 37:3357–3366CrossRef
144.
Burtenshaw SM, Cannell AJ, McAlister ED et al (2016) Toward observation as first-line management in abdominal desmoid tumors. Ann Surg Oncol 23:2212–2219PubMedCrossRef
145.
Utsunomiya J, Iwama T, Imajo M et al (1980) Total colectomy, mucosal proctectomy, and ileoanal anastomosis. Dis Colon Rectum 23:459–466PubMedCrossRef
146.
McMullen K, Hicks TC, Ray JE et al (1991) Complications associated with ileal pouch-anal anastomosis. World J Surg 15:763–766PubMedCrossRef
147.
Ganschow P, Trauth S, Hinz U et al (2018) Risk factors associated with pouch adenomas in patients with familial adenomatous polyposis. Dis Colon Rectum 61:1096–1101PubMedCrossRef
148.
Bertario L, Russo A, Radice P et al (2000) Genotype and phenotype factors as determinants for rectal stump cancer in patients with familial adenomatous polyposis. Hereditary Colorectal Tumors Registry. Ann Surg 231:538–543PubMedPubMedCentralCrossRef
149.
150.
Aziz O, Athanasiou T, Fazio VW et al (2006) Meta-analysis of observational studies of ileorectal versus ileal pouch-anal anastomosis for familial adenomatous polyposis. Br J Surg 93:407–417PubMedCrossRef
151.
Yamadera M, Ueno H, Kobayashi H et al (2017) Current status of prophylactic surgical treatment for familial adenomatous polyposis in Japan. Surg Today 47:690–696PubMedCrossRef
152.
Ishikawa H, Mutoh M, Iwama T et al (2016) Endoscopic management of familial adenomatous polyposis in patients refusing colectomy. Endoscopy 48:51–55PubMedCrossRef
153.
Weston-Petrides GK, Lovegrove RE, Tilney HS et al (2008) Comparison of outcomes after restorative proctocolectomy with or without defunctioning ileostomy. Arch Surg 143:406–412PubMedCrossRef
154.
Remzi FH, Fazio VW, Gorgun E et al (2006) The outcome after restorative proctocolectomy with or without defunctioning ileostomy. Dis Colon Rectum 49:470–477PubMedCrossRef
155.
Ganschow P, Warth R, Hinz U et al (2014) Early postoperative complications after stapled vs handsewn restorative proctocolectomy with ileal pouch-anal anastomosis in 148 patients with familial adenomatous polyposis coli: a matched-pair analysis. Colorectal Dis 16:116–122PubMedCrossRef
156.
Mozafar M, Shateri K, Tabatabaey A et al (2014) Familial adenomatous polyposis: ileo-anal pouch versus ileo-rectal anastomosis. Gastroenterol Hepatol Bed Bench 7:206–210PubMedPubMedCentral
157.
Kennedy RD, Zarroug AE, Moir CR et al (2014) Ileal pouch anal anastomosis in pediatric familial adenomatous polyposis: a 24-year review of operative technique and patient outcomes. J Pediatr Surg 49:1409–1412PubMedCrossRef
158.
Möslein G (2016) Surgical considerations in FAP-related pouch surgery: could we do better? Fam Cancer 15:457–466PubMedCrossRef
159.
Tanaka M, Kanemitsu Y, Ueno H et al (2017) Prognostic impact of hospital volume on familial adenomatous polyposis: a nationwide multicenter study. Int J Colorectal Dis 32:1489–1498PubMedCrossRef
160.
Mennigen R, Sewald W, Senninger N et al (2014) Morbidity of loop ileostomy closure after restorative proctocolectomy for ulcerative colitis and familial adenomatous polyposis: a systematic review. J Gastrointest Surg 18:2192–2200PubMedCrossRef
161.
Kjaer MD, Laursen SB, Qvist N et al (2014) Sexual function and body image are similar after laparoscopy-assisted and open ileal pouch-anal anastomosis. World J Surg 38:2460–2465PubMedCrossRef
162.
Fajardo AD, Dharmarajan S, George V et al (2010) Laparoscopic versus open 2-stage ileal pouch: laparoscopic approach allows for faster restoration of intestinal continuity. J Am Coll Surg 211:377–383PubMedCrossRef
163.
da Luz MA, Church JM, Burke CA (2009) The evolution of prophylactic colorectal surgery for familial adenomatous polyposis. Dis Colon Rectum 52:1481–1486CrossRef
164.
McKenna NP, Potter DD, Bews KA et al (2019) Ileal-pouch anal anastomosis in pediatric NSQIP: Does a laparoscopic approach reduce complications and length of stay? J Pediatr Surg 54:112–117PubMedCrossRef
165.
Kauffman JD, Snyder CW, Danielson PD et al (2019) 30–Day Outcomes of laparoscopic versus open total proctocolectomy with ileoanal anastomosis in children and young adults: a combined analysis of the National Surgical Quality Improvement Project Pediatric and Adult Databases. J Laparoendosc Adv Surg Tech A 29:402–408PubMedCrossRef
166.
Campos FG, Real Martinez CA, Monteiro de Camargo MG et al (2018) Laparoscopic versus open restorative proctocolectomy for familial adenomatous polyposis. J Laparoendosc Adv Surg Tech A 28:47–52PubMedCrossRef
167.
Zhang Z, Wang D, Xu C et al (2019) Laparoscopy adjuvant total proctocolectomy for the treatment of familial adenomatous polyposis (FAP). Clin Transl Oncol 21:753–759PubMedCrossRef
168.
Sinha A, Burns EM, Latchford A et al (2018) Risk of desmoid formation after laparoscopic versus open colectomy and ileorectal anastomosis for familial adenomatous polyposis. BJS Open 2:452–455PubMedPubMedCentralCrossRef
169.
Chittleborough TJ, Warrier SK, Heriot AG et al (2017) Dispelling misconceptions in the management of familial adenomatous polyposis. ANZ J Surg 87:441–445PubMedCrossRef
170.
Kitano S, Inomata M, Mizusawa J et al (2017) Survival outcomes following laparoscopic versus open D3 dissection for stage II or III colon cancer (JCOG0404): a phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol 2:261–268PubMedCrossRef
171.
Bonjer HJ, Deijen CL, Abis GA et al (2015) A randomized trial of laparoscopic versus open surgery for rectal cancer. N Engl J Med 372:1324–1332PubMedCrossRef
172.
173.
174.
Giardiello FM, Hamilton SR, Krush AJ et al (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328:1313–1316PubMedCrossRef
175.
Labayle D, Fischer D, Vielh P et al (1991) Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101:635–639PubMedCrossRef
176.
Nugent KP, Farmer KC, Spigelman AD et al (1993) Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 80:1618–1619PubMedCrossRef
177.
Cruz-Correa M, Hylind LM, Romans KE et al (2002) Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology 122:641–645PubMedCrossRef
178.
Steinbach G, Lynch PM, Phillips RK et al (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946–1952PubMedCrossRef
179.
Solomon SD, McMurray JJ, Pfeffer MA et al (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352:1071–1080PubMedCrossRef
180.
West NJ, Clark SK, Phillips RK et al (2010) Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis. Gut 59:918–925PubMedCrossRef
181.
Hull MA, Sprange K, Hepburn T et al (2018) Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2 x 2 factorial trial. Lancet 392:2583–2594PubMedPubMedCentralCrossRef
182.
Burn J, Bishop DT, Chapman PD et al (2011) A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res (Phila) 4:655–665CrossRef
183.
Ishikawa H, Wakabayashi K, Suzuki S et al (2013) Preventive effects of low-dose aspirin on colorectal adenoma growth in patients with familial adenomatous polyposis: double-blind, randomized clinical trial. Cancer Med 2:50–56PubMedPubMedCentralCrossRef
184.
Herraiz M, Barbesino G, Faquin W et al (2007) Prevalence of thyroid cancer in familial adenomatous polyposis syndrome and the role of screening ultrasound examinations. Clin Gastroenterol Hepatol 5:367–373PubMedCrossRef
185.
Steinhagen E, Guillem JG, Chang G et al (2012) The prevalence of thyroid cancer and benign thyroid disease in patients with familial adenomatous polyposis may be higher than previously recognized. Clin Colorectal Cancer 11:304–308PubMedCrossRef
186.
Harach HR, Williams GT, Williams ED (1994) Familial adenomatous polyposis associated thyroid carcinoma: a distinct type of follicular cell neoplasm. Histopathology 25:549–561PubMedCrossRef
187.
Cameselle-Teijeiro J, Chan JK (1999) Cribriform-morular variant of papillary carcinoma: a distinctive variant representing the sporadic counterpart of familial adenomatous polyposis-associated thyroid carcinoma? Mod Pathol 12:400–411PubMed
188.
189.
Attard TM, Giglio P, Koppula S et al (2007) Brain tumors in individuals with familial adenomatous polyposis: a cancer registry experience and pooled case report analysis. Cancer 109:761–766PubMedCrossRef
190.
Shiroky JS, Lerner-Ellis JP, Govindarajan A et al (2018) Characteristics of adrenal masses in familial adenomatous polyposis. Dis Colon Rectum 61:679–685PubMedCrossRef
191.
Smith TG, Clark SK, Katz DE et al (2000) Adrenal masses are associated with familial adenomatous polyposis. Dis Colon Rectum 43:1739–1742PubMedCrossRef
192.
Marchesa P, Fazio VW, Church JM et al (1997) Adrenal masses in patients with familial adenomatous polyposis. Dis Colon Rectum 40:1023–1028PubMedCrossRef
193.
Burke CA, Santisi J, Church J et al (2005) The utility of capsule endoscopy small bowel surveillance in patients with polyposis. Am J Gastroenterol 100:1498–1502PubMedCrossRef
194.
Cavallo D, Ballardini G, Ferrari A et al (2016) Wireless capsule endoscopy in adolescents with familial adenomatous polyposis. Tumori 102:40–44PubMedCrossRef
195.
Yamada A, Watabe H, Iwama T et al (2014) The prevalence of small intestinal polyps in patients with familial adenomatous polyposis: a prospective capsule endoscopy study. Fam Cancer 13:23–28PubMedCrossRef
196.
Iaquinto G, Fornasarig M, Quaia M et al (2008) Capsule endoscopy is useful and safe for small-bowel surveillance in familial adenomatous polyposis. Gastrointest Endosc 67:61–67PubMedCrossRef
197.
Araujo IK, Pages M, Romero C et al (2017) Twelve-year asymptomatic retention of a colon capsule endoscope. Gastrointest Endosc 85:681–682PubMedCrossRef
198.
Schulmann K, Hollerbach S, Kraus K et al (2005) Feasibility and diagnostic utility of video capsule endoscopy for the detection of small bowel polyps in patients with hereditary polyposis syndromes. Am J Gastroenterol 100:27–37PubMedCrossRef
199.
Dunlop MG, Farrington SM, Carothers AD et al (1997) Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 6:105–110PubMedCrossRef
200.
Barrow E, Alduaij W, Robinson L et al (2008) Colorectal cancer in HNPCC: cumulative lifetime incidence, survival and tumour distribution. A report of 121 families with proven mutations. Clin Genet 74:233–242PubMedCrossRef
201.
Grover S, Syngal S (2009) Genetic testing in gastroenterology: Lynch syndrome. Best Pract Res Clin Gastroenterol 23:185–196PubMedCrossRef
202.
Win AK, Young JP, Lindor NM et al (2012) Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol 30:958–964PubMedPubMedCentralCrossRef
203.
204.
Barrow E, Robinson L, Alduaij W et al (2009) Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin Genet 75:141–149PubMedCrossRef
205.
Hampel H, Stephens JA, Pukkala E et al (2005) Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology 129:415–421PubMedCrossRef
206.
207.
Aarnio M, Sankila R, Pukkala E et al (1999) Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 81:214–218PubMedCrossRef
208.
209.
210.
Kempers MJ, Kuiper RP, Ockeloen CW et al (2011) Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol 12:49–55PubMedCrossRef
211.
Kuiper RP, Vissers LE, Venkatachalam R et al (2011) Recurrence and variability of germline EPCAM deletions in Lynch syndrome. Hum Mutat 32:407–414PubMedCrossRef
212.
Lynch HT, Shaw MW, Magnuson CW et al (1966) Hereditary factors in cancer. Study of two large midwestern kindreds. Arch Intern Med 117:206–212PubMedCrossRef
213.
Boland CR, Troncale FJ (1984) Familial colonic cancer without antecedent polyposis. Ann Intern Med 100:700–701PubMedCrossRef
214.
Vasen HF, Mecklin JP, Khan PM et al (1991) The International Collaborative Group on hereditary non-polyposis colorectal cancer (ICG–HNPCC). Dis Colon Rectum 34:424–425PubMedCrossRef
215.
Vasen HF (2000) Clinical diagnosis and management of hereditary colorectal cancer syndromes. J Clin Oncol 18:81s–92sPubMed
216.
Suter CM, Martin DI, Ward RL (2004) Germline epimutation of MLH1 in individuals with multiple cancers. Nat Genet 36:497–501PubMedCrossRef
217.
Umar A, Boland CR, Terdiman JP et al (2004) Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96:261–268PubMedCrossRef
218.
Ladabaum U, Ford JM, Martel M et al (2015) American Gastroenterological Association technical review on the diagnosis and management of Lynch syndrome. Gastroenterology 149(783–813):e20
219.
Moreira L, Balaguer F, Lindor N et al (2012) Identification of Lynch syndrome among patients with colorectal cancer. JAMA 308:1555–1565PubMedCrossRef
220.
Jiang W, Cai MY, Li SY et al (2019) Universal screening for Lynch syndrome in a large consecutive cohort of Chinese colorectal cancer patients: high prevalence and unique molecular features. Int J Cancer 144:2161–2168PubMedCrossRef
221.
Japanese Society of Medical Oncology (2016) Guidance of genetic-related testing in colorectal cancer practice, 3rd edn. Kanehara & Co. Ltd, Tokyo
222.
Piñol V, Castells A, Andreu M et al (2005) Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 293:1986–1994PubMedCrossRef
223.
Furukawa Y (2010) Review of hereditary colorectal cancer [HNPCC]—current state in Japan. Front Colorectal Cancer 3:120–124
224.
Jenkins MA, Hayashi S, O’Shea AM et al (2007) Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. Gastroenterology 133:48–56PubMedCrossRef
225.
Aaltonen LA, Peltomäki P, Mecklin JP et al (1994) Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. Cancer Res 54:1645–1648PubMed
226.
Aaltonen LA, Salovaara R, Kristo P et al (1998) Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 338:1481–1487PubMedCrossRef
227.
Peltomäki P (2003) Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol 21:1174–1179PubMedCrossRef
228.
Ishikubo T, Nishimura Y, Yamaguchi K et al (2004) The clinical features of rectal cancers with high-frequency microsatellite instability (MSI-H) in Japanese males. Cancer Lett 216:55–62PubMedCrossRef
229.
Asaka S, Arai Y, Nishimura Y et al (2009) Microsatellite instability-low colorectal cancer acquires a KRAS mutation during the progression from Dukes’ A to Dukes’ B. Carcinogenesis 30:494–499PubMedCrossRef
230.
Jiricny J, Nyström-Lahti M (2000) Mismatch repair defects in cancer. Curr Opin Genet Dev 10:157–161PubMedCrossRef
231.
Barnetson RA, Tenesa A, Farrington SM et al (2006) Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med 354:2751–2763PubMedCrossRef
232.
Shia J, Tang LH, Vakiani E et al (2009) Immunohistochemistry as first-line screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: a 2-antibody panel may be as predictive as a 4-antibody panel. Am J Surg Pathol 33:1639–1645PubMedCrossRef
233.
Shia J, Zhang L, Shike M et al (2013) Secondary mutation in a coding mononucleotide tract in MSH6 causes loss of immunoexpression of MSH6 in colorectal carcinomas with MLH1/PMS2 deficiency. Mod Pathol 26:131–138PubMedCrossRef
234.
Adar T, Rodgers LH, Shannon KM et al (2018) Universal screening of both endometrial and colon cancers increases the detection of Lynch syndrome. Cancer 124:3145–3153PubMedCrossRef
235.
Vasen HF, Blanco I, Aktan-Collan K et al (2013) Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 62:812–823PubMedCrossRef
236.
Giardiello FM, Allen JI, Axilbund JE et al (2014) Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on colorectal cancer. Gastroenterology 147:502–526PubMedCrossRef
237.
Stoffel EM, Mangu PB, Gruber SB et al (2015) Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology clinical practice guidelines. J Clin Oncol 33:209–217PubMedCrossRef
238.
239.
Senter L, Clendenning M, Sotamaa K et al (2008) The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology 135(419–428):e411
240.
Yanaba K, Nakagawa H, Takeda Y et al (2008) Muir–Torre syndrome caused by partial duplication of MSH2 gene by Alu-mediated nonhomologous recombination. Br J Dermatol 158:150–156PubMed
241.
Kanamori M, Kon H, Nobukuni T et al (2000) Microsatellite instability and the PTEN1 gene mutation in a subset of early onset gliomas carrying germline mutation or promoter methylation of the hMLH1 gene. Oncogene 19:1564–1571PubMedCrossRef
242.
de Jong AE, Hendriks YM, Kleibeuker JH et al (2006) Decrease in mortality in Lynch syndrome families because of surveillance. Gastroenterology 130:665–671PubMedCrossRef
243.
Kane MF, Loda M, Gaida GM et al (1997) Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 57:808–811PubMed
244.
Akagi K (2012) Study of clinicopathological features of colorectal cancers with KRAS and BRAF genetic mutations with different pathways. Colonic diseases now 2012. Japan Medical Center, Tokyo, pp 94–102
245.
Koinuma K, Shitoh K, Miyakura Y et al (2004) Mutations of BRAF are associated with extensive hMLH1 promoter methylation in sporadic colorectal carcinomas. Int J Cancer 108:237–242PubMedCrossRef
246.
McGivern A, Wynter CV, Whitehall VL et al (2004) Promoter hypermethylation frequency and BRAF mutations distinguish hereditary non-polyposis colon cancer from sporadic MSI-H colon cancer. Fam Cancer 3:101–107PubMedCrossRef
247.
Lindor NM, Rabe K, Petersen GM et al (2005) Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 293:1979–1985PubMedPubMedCentralCrossRef
248.
Yamaguchi T, Furukawa Y, Nakamura Y et al (2015) Comparison of clinical features between suspected familial colorectal cancer type X and Lynch syndrome in Japanese patients with colorectal cancer: a cross-sectional study conducted by the Japanese Society for Cancer of the colon and rectum. Jpn J Clin Oncol 45:153–159PubMedCrossRef
249.
Rodríguez-Soler M, Pérez-Carbonell L, Guarínos C et al (2013) Risk of cancer in cases of suspected lynch syndrome without germline mutation. Gastroenterology 144(926–932):e921
250.
251.
Arai M, Ogawa T, Chino A et al (2010) Incidence and pathological features of tumors on surveillance by colonoscopy and upper gastroduodenal endoscopy in patients with Lynch syndrome. J Fam Tumor 10:32–38
252.
Joost P, Therkildsen C, Dominguez-Valentin M et al (2015) Urinary tract cancer in Lynch syndrome; increased risk in carriers of MSH2 mutations. Urology 86:1212–1217PubMedCrossRef
253.
Ryan NAJ, Morris J, Green K et al (2017) Association of mismatch repair mutation with age at cancer onset in Lynch syndrome: implications for stratified surveillance strategies. JAMA Oncol 3:1702–1706PubMedPubMedCentralCrossRef
254.
Møller P, Seppälä T, Bernstein I et al (2017) Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut 66:464–472PubMedCrossRef
255.
Møller P, Seppälä TT, Bernstein I et al (2018) Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the prospective Lynch syndrome database. Gut 67:1306–1316PubMedCrossRef
256.
Committee on Practice Bulletins-Gynecology, Society of Gynecologic Oncology (2014) ACOG Practice Bulletin no. 147: Lynch syndrome. Obstet Gynecol 124:1042–1054CrossRef
257.
Auranen A, Joutsiniemi T (2011) A systematic review of gynecological cancer surveillance in women belonging to hereditary nonpolyposis colorectal cancer (Lynch syndrome) families. Acta Obstet Gynecol Scand 90:437–444PubMedCrossRef
258.
Chen LM, Yang KY, Little SE et al (2007) Gynecologic cancer prevention in Lynch syndrome/hereditary nonpolyposis colorectal cancer families. Obstet Gynecol 110:18–25PubMedCrossRef
259.
Järvinen HJ, Renkonen-Sinisalo L, Aktán-Collán K et al (2009) Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol 27:4793–4797PubMedCrossRef
260.
Renkonen-Sinisalo L, Bützow R, Leminen A et al (2007) Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. Int J Cancer 120:821–824PubMedCrossRef
261.
Rijcken FE, Mourits MJ, Kleibeuker JH et al (2003) Gynecologic screening in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 91:74–80PubMedCrossRef
262.
Dove-Edwin I, Boks D, Goff S et al (2002) The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. Cancer 94:1708–1712PubMedCrossRef
263.
Yang KY, Caughey AB, Little SE et al (2011) A cost–effectiveness analysis of prophylactic surgery versus gynecologic surveillance for women from hereditary non-polyposis colorectal cancer (HNPCC) families. Fam Cancer 10:535–543PubMedCrossRef
264.
Schmeler KM, Lynch HT, Chen LM et al (2006) Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 354:261–269PubMedCrossRef
265.
Stuckless S, Green J, Dawson L et al (2013) Impact of gynecological screening in Lynch syndrome carriers with an MSH2 mutation. Clin Genet 83:359–364PubMedCrossRef
266.
Hampel H, Frankel WL, Martin E et al (2008) Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 26:5783–5788PubMedPubMedCentralCrossRef
267.
Sharaf RN, Myer P, Stave CD et al (2013) Uptake of genetic testing by relatives of Lynch syndrome probands: a systematic review. Clin Gastroenterol Hepatol 11:1093–1100PubMedCrossRef
268.
Hampel H (2016) Genetic counseling and cascade genetic testing in Lynch syndrome. Fam Cancer 15:423–427PubMedCrossRef
269.
Japanese Association of Medical Sciences (2011) Guidelines for genetic tests and diagnoses in medical practice. J Jpn Med Assoc 140:355–361
270.
Anele CC, Adegbola SO, Askari A et al (2017) Risk of metachronous colorectal cancer following colectomy in Lynch syndrome: a systematic review and meta-analysis. Colorectal Dis 19:528–536PubMedCrossRef
271.
Malik SS, Lythgoe MP, McPhail M et al (2018) Metachronous colorectal cancer following segmental or extended colectomy in Lynch syndrome: a systematic review and meta-analysis. Fam Cancer 17:557–564PubMedCrossRef
272.
Nagasaki T, Arai M, Chino A et al (2018) Feasibility of segmental colectomy followed by endoscopic surveillance as a treatment strategy for colorectal cancer patients with Lynch syndrome. Dig Surg 35:448–456PubMedCrossRef
273.
Win AK, Parry S, Parry B et al (2013) Risk of metachronous colon cancer following surgery for rectal cancer in mismatch repair gene mutation carriers. Ann Surg Oncol 20:1829–1836PubMedPubMedCentralCrossRef
274.
Sinicrope FA, Foster NR, Thibodeau SN et al (2011) DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst 103:863–875PubMedPubMedCentralCrossRef
275.
Des Guetz G, Schischmanoff O, Nicolas P et al (2009) Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur J Cancer 45:1890–1896PubMedCrossRef
276.
Webber EM, Kauffman TL, O’Connor E et al (2015) Systematic review of the predictive effect of MSI status in colorectal cancer patients undergoing 5FU-based chemotherapy. BMC Cancer 15:156PubMedPubMedCentralCrossRef
277.
André T, de Gramont A, Vernerey D et al (2015) Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. J Clin Oncol 33:4176–4187PubMedCrossRef
278.
Tran B, Kopetz S, Tie J et al (2011) Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 117:4623–4632PubMedCrossRef
279.
Venderbosch S, Nagtegaal ID, Maughan TS et al (2014) Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res 20:5322–5330PubMedPubMedCentralCrossRef
280.
Fallik D, Borrini F, Boige V et al (2003) Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res 63:5738–5744PubMed
281.
Innocenti F, Ou FS, Qu X et al (2019) Mutational analysis of patients with colorectal cancer in CALGB/SWOG 80405 identifies new roles of microsatellite instability and tumor mutational burden for patient outcome. J Clin Oncol 37:1217–1227PubMedPubMedCentralCrossRef
282.
283.
284.
Overman MJ, McDermott R, Leach JL et al (2017) Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 18:1182–1191PubMedPubMedCentralCrossRef
285.
Overman MJ, Lonardi S, Wong KYM et al (2018) Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol 36:773–779PubMedCrossRef
286.
Botma A, Nagengast FM, Braem MG et al (2010) Body mass index increases risk of colorectal adenomas in men with Lynch syndrome: the GEOLynch cohort study. J Clin Oncol 28:4346–4353PubMedCrossRef
287.
Movahedi M, Bishop DT, Macrae F et al (2015) Obesity, aspirin, and risk of colorectal cancer in carriers of hereditary colorectal cancer: a prospective investigation in the CAPP2 study. J Clin Oncol 33:3591–3597PubMedCrossRef
288.
Tanakaya K, Furukawa Y, Nakamura Y et al (2015) Relationship between smoking and multiple colorectal cancers in patients with Japanese Lynch syndrome: a cross-sectional study conducted by the Japanese Society for Cancer of the Colon and Rectum. Jpn J Clin Oncol 45:307–310PubMedCrossRef
289.
van Duijnhoven FJ, Botma A, Winkels R et al (2013) Do lifestyle factors influence colorectal cancer risk in Lynch syndrome? Fam Cancer 12:285–293PubMedCrossRef
290.
Winkels RM, Botma A, Van Duijnhoven FJ et al (2012) Smoking increases the risk for colorectal adenomas in patients with Lynch syndrome. Gastroenterology 142:241–247PubMedCrossRef
291.
Chau R, Dashti SG, Ait Ouakrim D et al (2016) Multivitamin, calcium and folic acid supplements and the risk of colorectal cancer in Lynch syndrome. Int J Epidemiol 45:940–953PubMedPubMedCentralCrossRef
292.
Diergaarde B, Braam H, Vasen HF et al (2007) Environmental factors and colorectal tumor risk in individuals with hereditary nonpolyposis colorectal cancer. Clin Gastroenterol Hepatol 5:736–742PubMedCrossRef
293.
Kamiza AB, Hsieh LL, Tang R et al (2015) (2015) Risk factors associated with colorectal cancer in a subset of patients with mutations in MLH1 and MSH2 in Taiwan fulfilling the Amsterdam II Criteria for Lynch syndrome. PLoS ONE 10:e0130018PubMedPubMedCentralCrossRef
294.
Dashti SG, Buchanan DD, Jayasekara H et al (2017) Alcohol Consumption and the Risk of Colorectal Cancer for Mismatch Repair Gene Mutation Carriers. Cancer Epidemiol Biomarkers Prev 26:366–375PubMedCrossRef
295.
Miguchi M, Hinoi T, Tanakaya K et al (2018) Alcohol consumption and early-onset risk of colorectal cancer in Japanese patients with Lynch syndrome: a cross-sectional study conducted by the Japanese Society for Cancer of the Colon and Rectum. Surg Today 48:810–814PubMedCrossRef
296.
297.
Burn J, Gerdes AM, Macrae F et al (2011) Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 378:2081–2087PubMedPubMedCentralCrossRef
298.
Rothwell PM, Cook NR, Gaziano JM et al (2018) Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet 392:387–399PubMedPubMedCentralCrossRef
299.
Järvinen HJ, Aarnio M, Mustonen H et al (2000) Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118:829–834PubMedCrossRef
300.
Vasen HF, Nagengast FM, Khan PM (1995) Interval cancers in hereditary non-polyposis colorectal cancer (Lynch syndrome). Lancet 345:1183–1184PubMedCrossRef
301.
Engel C, Rahner N, Schulmann K et al (2010) Efficacy of annual colonoscopic surveillance in individuals with hereditary nonpolyposis colorectal cancer. Clin Gastroenterol Hepatol 8:174–182PubMedCrossRef
302.
Engel C, Vasen HF, Seppälä T et al (2018) No difference in colorectal cancer incidence or stage at detection by colonoscopy among 3 countries with different Lynch syndrome surveillance policies. Gastroenterology 155(1400–1409):e1402
303.
Seppälä TT, Ahadova A, Dominguez-Valentin M et al (2019) Lack of association between screening interval and cancer stage in Lynch syndrome may be accounted for by over-diagnosis; a prospective Lynch syndrome database report. Hered Cancer Clin Pract 17:8PubMedPubMedCentralCrossRef
304.
Vasen HF, Watson P, Mecklin JP et al (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 116:1453–1456PubMedCrossRef
305.
306.
Jass JR, Cottier DS, Pokos V et al (1997) Mixed epithelial polyps in association with hereditary non-polyposis colorectal cancer providing an alternative pathway of cancer histogenesis. Pathology 29:28–33PubMedCrossRef
307.
Ahadova A, Gallon R, Gebert J et al (2018) Three molecular pathways model colorectal carcinogenesis in Lynch syndrome. Int J Cancer 143:139–150PubMedCrossRef
Metadata
Title
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2020 for the Clinical Practice of Hereditary Colorectal Cancer
Authors
Naohiro Tomita
Hideyuki Ishida
Kohji Tanakaya
Tatsuro Yamaguchi
Kensuke Kumamoto
Toshiaki Tanaka
Takao Hinoi
Yasuyuki Miyakura
Hirotoshi Hasegawa
Tetsuji Takayama
Hideki Ishikawa
Takeshi Nakajima
Akiko Chino
Hideki Shimodaira
Akira Hirasawa
Yoshiko Nakayama
Shigeki Sekine
Kazuo Tamura
Kiwamu Akagi
Yuko Kawasaki
Hirotoshi Kobayashi
Masami Arai
Michio Itabashi
Yojiro Hashiguchi
Kenichi Sugihara
Japanese Society for Cancer of the Colon, Rectum
Publication date
01-08-2021
Publisher
Springer Singapore
Published in
International Journal of Clinical Oncology / Issue 8/2021
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-021-01881-4

Other articles of this Issue 8/2021

International Journal of Clinical Oncology 8/2021 Go to the issue

Invited Review Article

Perspectives for circulating tumor DNA in clinical management of colorectal cancer

Original Article

On-treatment C-reactive protein control could predict response to subsequent anti-PD-1 treatment in metastatic renal cell carcinoma

Original Article

Clinico-pathological characteristics of patients with stage IB1–IB2 (FIGO 2018) uterine cervical cancer: a nationwide study in Japan

Invited Review Article

The usefulness of microRNA in urine and saliva as a biomarker of gastroenterological cancer

Original Article

Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab

Original Article

Polymorphism of TUSC7 associated with gastric cancer susceptibility and binding with miR-133a-3p: a population-based case–control study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits